CORRECTION

Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

Vasilios Liapis¹ , William Tieu^{2,3} , Nicole L. Wittwer¹ , Tessa Gargett¹ , Andreas Evdokiou⁴ , Prab Takhar³, Stacey E. Rudd⁵ , Paul S. Donnelly⁵ , Michael P. Brown^{1,2,6} , and Alexander H. Staudacher^{1,2}

¹*Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Level 9 University of South Australia Health Innovation Building, North Terrace, Adelaide 5000, Australia*

²*School of Medicine, University of Adelaide, Adelaide, SA 5000, Australia*

³*Molecular Imaging and Therapy Research Unit (MITRU), South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia*

⁴*Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Woodville, SA 5011, Australia*

⁵*School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia*

⁶*Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia 2021*

Correction to: Mol Imaging Biol (2021)

<https://doi.org/10.1007/s11307-021-01620-1>

This article was updated to amend the Acknowledgments.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.